< Back to search
Filter
Featured

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

for
Von Willebrand Disease, Type 3
Location: Montreal, Richmond VA, Toronto, Gainesville FL,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 0+

Code: NCT06998524

Phase3, Recruiting
Featured

Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.

for
Cardiovascular Diseases, Metabolic Syndrome, Obesity,
Location: Brooklyn NY
Sponsor: Clindove Research LLC

Sex: All

Age: 18+

Code: NCT07106879

Recruiting
Featured

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

for
Non-Squamous Non-Small Cell Lung Cancer, c-MET
Location: Ottawa, Fairfax VA, Orange City FL, Houston TX,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07005102

Phase2, Phase3, Recruiting
Featured

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

for
Ulcerative Colitis
Location: Morristown NJ, Philadelphia PA, Miami FL, Pittsburgh PA,
Sponsor: AbbVie

Sex: All

Age: 2 - 17

Code: NCT07071519

Phase3, Recruiting
Featured

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

for
Breast Cancer
Location: Boston MA, East Patchogue NY, The Bronx NY,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT07100106

Phase1, Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Featured

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

for
Breast Cancer
Location: Montreal, Morgantown WV, Toronto, Germantown TN,
Sponsor: Hoffmann-La Roche

Sex: Female

Age: 18+

Code: NCT07054190

Phase2, Recruiting
Featured

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

for
Atherosclerosis
Location: New Haven CT, North Massapequa NY, Chapel Hill NC,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT07448038

Phase2, Recruiting
Featured

Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data

for
Hepatitis C Virus (HCV)
Location: Toronto, Vancouver
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07419347

Recruiting
Featured

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

for
Breast Cancer
Location: Chicoutimi, Montreal, Ottawa, Toronto, Jacksonville FL,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT07405801

Phase2, Recruiting
Featured

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair

for
Ventral Hernia
Location: Hershey PA, Wilmington NC, Miami FL, Roanoke VA,
Sponsor: AbbVie

Sex: All

Age: 18 - 70+

Code: NCT07226791

Phase2, Recruiting
Featured

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

for
Atopic Dermatitis
Location: Montreal, Lanham MD, Coral Gables FL, Charleston SC,
Sponsor: AbbVie

Sex: All

Age: 2 - 11

Code: NCT06461897

Phase3, Recruiting
Featured

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

for
Breast Cancer
Location: Moncton, Shirley NY, The Bronx NY, New York NY,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06790693

Phase3, Recruiting
Featured

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

for
Crohn's Disease
Location: Waltham MA, New York NY, Morristown NJ, Orlando FL,
Sponsor: AbbVie

Sex: All

Age: 2 - 17

Code: NCT05995353

Phase3, Recruiting
Featured

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

for
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Location: Boston MA, Albany NY, Virginia Beach VA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06806033

Phase2, Recruiting
Featured

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

for
Neovascular Age-related Macular Degeneration
Location: Hickory NC, Austin TX
Sponsor: Genentech, Inc.

Sex: All

Age: 50+

Code: NCT04853251

Recruiting
Featured

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

for
Chronic Migraine
Location: Nashua NH, Philadelphia PA, Miami FL, Weston FL,
Sponsor: AbbVie

Sex: All

Age: 12 - 17

Code: NCT06810505

Phase3, Recruiting
Featured

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

for
Cancer
Location: Toronto
Sponsor: Hoffmann-La Roche

Sex: All

Age: 0+

Code: NCT05862285

Phase3, Recruiting
Featured

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

for
Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment,
Location: Morrisville NC
Sponsor: AbbVie

Sex: Female

Age: 0+

Code: NCT04846959

Recruiting
Featured

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

for
Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Location: St. John's, Moncton, Kingston, Greater Sudbury,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06830759

Recruiting
Featured

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

for
Migraine
Location: Nashua NH, Stamford CT, Morristown NJ, Philadelphia PA,
Sponsor: AbbVie

Sex: All

Age: 6 - 17

Code: NCT05125302

Phase3, Recruiting